#None #Paris #Plaque Psoriasis #AC-201 #Accro Bioscience

Accro Bioscience to Present Phase II Data of AC-201

Accro Bioscience, operating under the name Accropeutics, is poised to present findings from a pivotal Phase II clinical trial at the upcoming European Academy of Dermatology and Venereology (EADV) Congress scheduled from September 17-20, 2025, in Paris. The focus of this presentation will be on AC-201, an innovative oral selective TYK2/JAK1 inhibitor designed for patients with moderate-to-severe plaque psoriasis.

Presentation Details

The presentation is set for September 19, 2025, during the Late Breaking Sessions and will be identified by Abstract ID LBA-5. The title of the research will be "Efficacy and Safety of a Selective Oral TYK2/JAK1 Inhibitor, AC-201, in Patients with Plaque Psoriasis: A Phase II, Randomized, Double-blinded, Placebo-Controlled Trial." It will take place in the Paris Nord session room from 17:15 to 17:30.

About AC-201

AC-201 stands out as a cutting-edge small-molecule inhibitor of TYK2/JAK1, uniquely targeting the pseudo-kinase domain (JH2) of both tyrosine kinases with secondary effects limited on the JAK2/JAK2 signaling pathway. Its development is primarily for treating immune-mediated inflammatory diseases, including psoriasis, cutaneous lupus erythematosus, and non-infectious uveitis. Initial Phase I studies carried out on healthy volunteers in both China and Australia indicated that AC-201 is generally safe and well-tolerated at various dosage levels, with no severe adverse events (SAEs) reported.

Accro Bioscience’s Mission

Accro Bioscience is a biotech firm that has gained recognition for its concentrated research on the molecular mechanisms underpinning regulated cell death in relation to human diseases. The company actively manages three clinical-stage assets, including AC-201, alongside a RIPK2 inhibitor (AC-101) and a RIPK1 inhibitor (AC-003). Both the RIPK2 inhibitor and the RIPK1 inhibitor have presented promising safety and pharmacokinetic data during their trials.

Innovations and Continued Research

The commitment of Accro Bioscience to furthering its innovative pipeline is evident in the progress of AC-201. After a successful Phase II clinical trial in psoriasis with favorable safety and efficacy results, Accro aims to solidify its position within a competitive market landscape filled with evolving treatment options for chronic skin disorders. Furthermore, AC-003 has received Orphan Drug Designation from the FDA, demonstrating the company’s dedication to addressing unmet medical needs in specialty populations.

As Accro Bioscience prepares to share its insights at EADV Congress, attendees can look forward to gaining an in-depth understanding of how therapies like AC-201 may reshape treatment protocols for patients suffering from plaque psoriasis and other immunological conditions. This event represents not only a milestone for the company but also a significant step forward in the realm of dermatological science and patient care.